{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:44Z","timestamp":1788307244203,"version":"build-2803163510"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,1,28]],"date-time":"2023-01-28T00:00:00Z","timestamp":1674864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,28]],"date-time":"2023-01-28T00:00:00Z","timestamp":1674864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Respir Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Without vaccination, an estimated 1 in 3 individuals will develop herpes zoster (HZ) in their lifetime. Increased risk of HZ is attributed to impaired cell-mediated immunity, as observed in age-related immunosenescence or in individuals immunocompromised due to disease or immunosuppressive treatments. Most vaccination guidelines recommend HZ vaccination in all adults\u2009\u2265\u200950\u00a0years of age, although Shingrix<jats:sup>\u00ae<\/jats:sup> was recently approved by the U.S. Food and Drug Administration for use in individuals aged\u2009\u2265\u200918\u00a0years who are or will be at increased risk of HZ due to immunodeficiency or immunosuppression caused by known disease or therapy, followed by approval by the European Medicines Agency for use in immunocompromised individuals aged\u2009\u2265\u200918\u00a0years. Chronic respiratory diseases are also risk factors for HZ. A new meta-analysis reported 24% and 41% increased risks of HZ in those with asthma and chronic obstructive pulmonary disorder (COPD), respectively, compared with healthy controls. Asthma and COPD increase a person\u2019s risk of HZ and associated complications at any age and may be further elevated in those receiving inhaled corticosteroids. Despite the increased risks, there is evidence that HZ vaccination uptake in those aged\u2009\u2265\u200950\u00a0years with COPD may be lower compared with the age-matched general population, potentially indicating a lack of awareness of HZ risk factors among clinicians and patients. The 2022 Global Initiative for Chronic Lung Disease report recognizes that Centers for Disease Control and Prevention recommended to vaccinate those aged\u2009\u2265\u200950\u00a0years against HZ, although health systems should consider the inclusion of all adults with asthma or COPD into their HZ vaccination programs. Further research into HZ vaccine efficacy\/effectiveness and safety in younger populations is needed to inform vaccination guidelines.<\/jats:p>\n                <jats:p><jats:bold>Graphical Abstract<\/jats:bold><\/jats:p>","DOI":"10.1186\/s12931-022-02305-1","type":"journal-article","created":{"date-parts":[[2023,1,28]],"date-time":"2023-01-28T14:03:06Z","timestamp":1674914586000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Risk factors for herpes zoster: should people with asthma or COPD be vaccinated?"],"prefix":"10.1186","volume":"24","author":[{"given":"Ekaterina","family":"Safonova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara P.","family":"Yawn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Welte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengbin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,28]]},"reference":[{"key":"2305_CR1","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1111\/j.1525-1497.2005.0150.x","volume":"20","author":"RP Insinga","year":"2005","unstructured":"Insinga RP, Itzler RF, Pellissier JM, Saddier P, Nikas AA. The incidence of herpes zoster in a United States administrative database. J Gen Intern Med. 2005;20:748\u201353.","journal-title":"J Gen Intern Med"},{"key":"2305_CR2","unstructured":"Harpaz R, Ortega-Sanchez IR, Seward JF, Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC). Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR: Recommendations and Reports. 2008;57:1\u201330."},{"key":"2305_CR3","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1017\/S0950268801005921","volume":"127","author":"M Brisson","year":"2001","unstructured":"Brisson M, Edmunds WJ, Law B, Gay NJ, Walld R, Brownell M, Roos LL, De Serres G. Epidemiology of varicella zoster virus infection in Canada and the United Kingdom. Epidemiol Infect. 2001;127:305\u201314.","journal-title":"Epidemiol Infect"},{"key":"2305_CR4","unstructured":"Centers for Disease Control and Prevention. Shingles (Herpes Zoster): clinical overview. https:\/\/www.cdc.gov\/shingles\/hcp\/clinical-overview.html. Accessed 1 Dec 2021."},{"key":"2305_CR5","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.4065\/82.11.1341","volume":"82","author":"BP Yawn","year":"2007","unstructured":"Yawn BP, Saddier P, Wollan PC, St Sauver JL, Kurland MJ, Sy LS. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc. 2007;82:1341\u20139.","journal-title":"Mayo Clin Proc"},{"key":"2305_CR6","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2014-004833","volume":"4","author":"K Kawai","year":"2014","unstructured":"Kawai K, Gebremeskel BG, Acosta CJ. Systematic review of incidence and complications of herpes zoster: towards a global perspective. BMJ Open. 2014;4: e004833.","journal-title":"BMJ Open"},{"key":"2305_CR7","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1212\/WNL.0b013e3182a3516e","volume":"81","author":"BP Yawn","year":"2013","unstructured":"Yawn BP, Gilden D. The global epidemiology of herpes zoster. Neurology. 2013;81:928\u201330.","journal-title":"Neurology"},{"key":"2305_CR8","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/j.mayocp.2013.03.014","volume":"88","author":"BP Yawn","year":"2013","unstructured":"Yawn BP, Wollan PC, St Sauver JL, Butterfield LC. Herpes zoster eye complications: rates and trends. Mayo Clin Proc. 2013;88:562\u201370.","journal-title":"Mayo Clin Proc"},{"key":"2305_CR9","doi-asserted-by":"publisher","first-page":"ofaa005","DOI":"10.1093\/ofid\/ofaa005","volume":"7","author":"F Marra","year":"2020","unstructured":"Marra F, Parhar K, Huang B, Vadlamudi N. Risk factors for herpes zoster infection: a meta-analysis. Open Forum Infect Dis. 2020;7:ofaa005.","journal-title":"Open Forum Infect Dis"},{"key":"2305_CR10","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1016\/j.mayocp.2017.10.009","volume":"92","author":"K Kawai","year":"2017","unstructured":"Kawai K, Yawn BP. Risk factors for herpes zoster: a systematic review and meta-analysis. Mayo Clin Proc. 2017;92:1806\u201321.","journal-title":"Mayo Clin Proc"},{"key":"2305_CR11","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1212\/WNL.0000000000002808","volume":"87","author":"HJ Forbes","year":"2016","unstructured":"Forbes HJ, Bhaskaran K, Thomas SL, Smeeth L, Clayton T, Mansfield K, Minassian C, Langan SM. Quantification of risk factors for postherpetic neuralgia in herpes zoster patients: a cohort study. Neurology. 2016;87:94\u2013102.","journal-title":"Neurology"},{"key":"2305_CR12","first-page":"571","volume":"25","author":"RE Hope-Simpson","year":"1975","unstructured":"Hope-Simpson RE. Postherpetic neuralgia. J R Coll Gen Pract. 1975;25:571\u20135.","journal-title":"J R Coll Gen Pract"},{"key":"2305_CR13","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1007\/BF03324909","volume":"21","author":"RW Johnson","year":"2009","unstructured":"Johnson RW. Herpes zoster and postherpetic neuralgia: a review of the effects of vaccination. Aging Clin Exp Res. 2009;21:236\u201343.","journal-title":"Aging Clin Exp Res"},{"key":"2305_CR14","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1007\/s13555-021-00535-7","volume":"11","author":"M Batram","year":"2021","unstructured":"Batram M, Witte J, Schwarz M, Hain J, Ultsch B, Steinmann M, Bhavsar A, Wutzler P, Criee CP, Hermann C, et al. Burden of herpes zoster in adult patients with underlying conditions: analysis of German claims data, 2007\u20132018. Dermatol Ther. 2021;11:1009\u201326.","journal-title":"Dermatol Ther"},{"key":"2305_CR15","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1111\/j.1346-8138.2011.01289.x","volume":"38","author":"M Zhang","year":"2011","unstructured":"Zhang M, Wu N, Yang L, Zhang J, Sun X, Zhong S, Ma X, Wang Y. Study on the T-helper cell 1\/2 cytokine profile in blister fluid of patients with herpes zoster and its clinical significance. J Dermatol. 2011;38:1158\u201362.","journal-title":"J Dermatol"},{"key":"2305_CR16","doi-asserted-by":"publisher","first-page":"136","DOI":"10.47102\/annals-acadmedsg.V38N2p136","volume":"38","author":"S Soyuncu","year":"2009","unstructured":"Soyuncu S, Berk Y, Eken C, Gulen B, Oktay C. Herpes zoster as a useful clinical marker of underlying cell-mediated immune disorders. Ann Acad Med Singap. 2009;38:136\u20138.","journal-title":"Ann Acad Med Singap"},{"key":"2305_CR17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0106501","volume":"9","author":"AL Pritchard","year":"2014","unstructured":"Pritchard AL, White OJ, Burel JG, Carroll ML, Phipps S, Upham JW. Asthma is associated with multiple alterations in anti-viral innate signalling pathways. PLoS ONE. 2014;9: e106501.","journal-title":"PLoS ONE"},{"key":"2305_CR18","unstructured":"Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. https:\/\/goldcopd.org\/wp-content\/uploads\/2021\/12\/GOLD-REPORT-2022-v1.1-22Nov2021_WMV.pdf. Accessed Dec 2021."},{"key":"2305_CR19","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.chest.2015.08.017","volume":"149","author":"PJ Barnes","year":"2016","unstructured":"Barnes PJ. Asthma-COPD overlap. Chest. 2016;149:7\u20138.","journal-title":"Chest"},{"key":"2305_CR20","unstructured":"Government of Canada. Herpes zoster (shingles) vaccine: Canadian immunization guide. https:\/\/www.canada.ca\/en\/public-health\/services\/publications\/healthy-living\/canadian-immunization-guide-part-4-active-vaccines\/page-8-herpes-zoster-(shingles)-vaccine.html. Accessed 15 Nov 2021."},{"key":"2305_CR21","unstructured":"Gobierno de Espa\u00f1a. Ponencia de Programa y Registro de Vacunaciones\u2014Recomendaciones de vacunaci\u00f3n frente a herpes z\u00f3ster [Presentation of the immunization program and records\u2014vaccination recommendations against herpes zoster]. https:\/\/www.mscbs.gob.es\/en\/profesionales\/saludPublica\/prevPromocion\/vacunaciones\/programasDeVacunacion\/docs\/HerpesZoster_RecomendacionesVacunacion.pdf. Accessed 15 Nov 2021."},{"key":"2305_CR22","unstructured":"World Health Organization. Asthma fact sheet. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/asthma. Accessed 15 Nov 2021."},{"key":"2305_CR23","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.jaci.2014.04.024","volume":"134","author":"YJ Juhn","year":"2014","unstructured":"Juhn YJ. Risks for infection in patients with asthma (or other atopic conditions): is asthma more than a chronic airway disease? J Allergy Clin Immunol. 2014;134:247\u201357.","journal-title":"J Allergy Clin Immunol"},{"key":"2305_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2017.11.015","volume":"120","author":"C Woehlk","year":"2018","unstructured":"Woehlk C, von Bulow A, Kriegbaum M, Backer V, Porsbjerg C. Allergic asthma is associated with increased risk of infections requiring antibiotics. Ann Allergy Asthma Immunol. 2018;120:169\u201376.e1.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"2305_CR25","doi-asserted-by":"publisher","first-page":"697","DOI":"10.4168\/aair.2021.13.5.697","volume":"13","author":"JH Kwon","year":"2021","unstructured":"Kwon JH, Wi CI, Seol HY, Park M, King K, Ryu E, Sohn S, Liu H, Juhn YJ. Risk, mechanisms and implications of asthma-associated infectious and inflammatory multimorbidities (AIMs) among individuals with asthma: a systematic review and a case study. Allergy Asthma Immunol Res. 2021;13:697\u2013718.","journal-title":"Allergy Asthma Immunol Res"},{"key":"2305_CR26","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s13223-020-00453-x","volume":"16","author":"SY Kim","year":"2020","unstructured":"Kim SY, Oh DJ, Choi HG. Asthma increases the risk of herpes zoster: a nested case-control study using a national sample cohort. Allergy Asthma Clin Immunol. 2020;16:52.","journal-title":"Allergy Asthma Clin Immunol"},{"key":"2305_CR27","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/j.iac.2014.07.002","volume":"34","author":"MK Perez","year":"2014","unstructured":"Perez MK, Piedimonte G. Metabolic asthma: is there a link between obesity, diabetes, and asthma? Immunol Allergy Clin North Am. 2014;34:777\u201384.","journal-title":"Immunol Allergy Clin North Am"},{"key":"2305_CR28","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jad.2014.04.027","volume":"166","author":"M Jiang","year":"2014","unstructured":"Jiang M, Qin P, Yang X. Comorbidity between depression and asthma via immune-inflammatory pathways: a meta-analysis. J Affect Disord. 2014;166:22\u20139.","journal-title":"J Affect Disord"},{"key":"2305_CR29","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.alit.2018.02.002","volume":"67","author":"A Uchida","year":"2018","unstructured":"Uchida A, Sakaue K, Inoue H. Epidemiology of asthma-chronic obstructive pulmonary disease overlap (ACO). Allergol Int. 2018;67:165\u201371.","journal-title":"Allergol Int"},{"key":"2305_CR30","unstructured":"World Health Organization. Chronic obstructive pulmonary disease (COPD) fact sheet. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/chronic-obstructive-pulmonary-disease-(copd). Accessed 15 Nov 2021."},{"key":"2305_CR31","doi-asserted-by":"publisher","first-page":"1900610","DOI":"10.1183\/13993003.00610-2019","volume":"54","author":"I Blanco","year":"2019","unstructured":"Blanco I, Diego I, Bueno P, Casas-Maldonado F, Miravitlles M. Geographic distribution of COPD prevalence in the world displayed by Geographic Information System maps. Eur Respir J. 2019;54:1900610.","journal-title":"Eur Respir J"},{"key":"2305_CR32","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1186\/s12879-018-3121-x","volume":"18","author":"C Munoz-Quiles","year":"2018","unstructured":"Munoz-Quiles C, Lopez-Lacort M, Diez-Domingo J. Risk and impact of herpes zoster among COPD patients: a population-based study, 2009\u20132014. BMC Infect Dis. 2018;18:203.","journal-title":"BMC Infect Dis"},{"key":"2305_CR33","first-page":"502","volume":"8","author":"P Ghaswalla","year":"2021","unstructured":"Ghaswalla P, Thompson-Leduc P, Cheng WY, Kunzweiler C, Wang MJ, Bogart M, Patterson BJ, Duh MS, Wojciehowski J, Park S, Yawn BP. Increased health care resource utilization and costs associated with herpes zoster among patients aged \u226550 years with chronic obstructive pulmonary disease in the United States. Chronic Obstr Pulm Dis. 2021;8:502\u201316.","journal-title":"Chronic Obstr Pulm Dis"},{"key":"2305_CR34","doi-asserted-by":"crossref","unstructured":"Global Initiative for Asthma. Global strategy for asthma management and prevention. https:\/\/ginasthma.org\/wp-content\/uploads\/2021\/05\/GINA-Main-Report-2021-V2-WMS.pdf. Accessed 15 Nov 2021.","DOI":"10.22266\/ijies2022.0831.31"},{"key":"2305_CR35","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1016\/j.jaci.2015.10.032","volume":"137","author":"HJ Kwon","year":"2016","unstructured":"Kwon HJ, Bang DW, Kim EN, Wi CI, Yawn BP, Wollan PC, Lahr BD, Ryu E, Juhn YJ. Asthma as a risk factor for zoster in adults: a population-based case-control study. J Allergy Clin Immunol. 2016;137:1406\u201312.","journal-title":"J Allergy Clin Immunol"},{"key":"2305_CR36","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1080\/02770903.2016.1211142","volume":"54","author":"YH Peng","year":"2017","unstructured":"Peng YH, Fang HY, Wu BR, Kao CH, Chen HJ, Hsia TC, Liao WC. Adult asthma is associated with an increased risk of herpes zoster: a population-based cohort study. J Asthma. 2017;54:250\u20137.","journal-title":"J Asthma"},{"key":"2305_CR37","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g2911","volume":"348","author":"HJ Forbes","year":"2014","unstructured":"Forbes HJ, Bhaskaran K, Thomas SL, Smeeth L, Clayton T, Langan SM. Quantification of risk factors for herpes zoster: population based case-control study. BMJ. 2014;348: g2911.","journal-title":"BMJ"},{"key":"2305_CR38","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/1471-2466-11-59","volume":"11","author":"P Ernst","year":"2011","unstructured":"Ernst P, Dell\u2019Aniello S, Mikaeloff Y, Suissa S. Risk of herpes zoster in patients prescribed inhaled corticosteroids: a cohort study. BMC Pulm Med. 2011;11:59.","journal-title":"BMC Pulm Med"},{"key":"2305_CR39","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s13601-020-00316-z","volume":"10","author":"I Kuprys-Lipinska","year":"2020","unstructured":"Kuprys-Lipinska I, Kolacinska-Flont M, Kuna P. New approach to intermittent and mild asthma therapy: evolution or revolution in the GINA guidelines? Clin Transl Allergy. 2020;10:19.","journal-title":"Clin Transl Allergy"},{"key":"2305_CR40","doi-asserted-by":"publisher","first-page":"A1771","DOI":"10.1016\/j.chest.2020.08.1547","volume":"158","author":"P Thompson-Leduc","year":"2020","unstructured":"Thompson-Leduc P, Ghaswalla P, Cheng W, Kunzweiler C, Wang M-J, Bogart M, Patterson B, Duh M, Wojciehowski J, Park S, Yawn B. COPD is associated with an increased risk of herpes zoster: a retrospective analysis of a United States claims database from 2013\u20132018. Chest. 2020;158:A1771\u20132.","journal-title":"Chest"},{"key":"2305_CR41","doi-asserted-by":"publisher","first-page":"E275","DOI":"10.1503\/cmaj.101137","volume":"183","author":"YW Yang","year":"2011","unstructured":"Yang YW, Chen YH, Wang KH, Wang CY, Lin HW. Risk of herpes zoster among patients with chronic obstructive pulmonary disease: a population-based study. CMAJ. 2011;183:E275\u201380.","journal-title":"CMAJ"},{"key":"2305_CR42","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1001\/jamaophthalmol.2013.6277","volume":"132","author":"DS Borkar","year":"2014","unstructured":"Borkar DS, Gonzales JA, Tham VM, Esterberg E, Vinoya AC, Parker JV, Uchida A, Acharya NR. Association between atopy and herpetic eye disease: results from the pacific ocular inflammation study. JAMA Ophthalmol. 2014;132:326\u201331.","journal-title":"JAMA Ophthalmol"},{"key":"2305_CR43","doi-asserted-by":"publisher","first-page":"S429","DOI":"10.1093\/infdis\/jiab387","volume":"224","author":"R Harbecke","year":"2021","unstructured":"Harbecke R, Cohen JI, Oxman MN. Herpes zoster vaccines. J Infect Dis. 2021;224:S429\u201342.","journal-title":"J Infect Dis"},{"key":"2305_CR44","first-page":"1528","volume":"60","author":"Centers for Disease Control and Prevention","year":"2011","unstructured":"Centers for Disease Control and Prevention. Update on herpes zoster vaccine: licensure for persons aged 50 through 59 years. MMWR Morb Mortal Wkly Rep. 2011;60:1528.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2305_CR45","unstructured":"European Medicines Agency. Zostavax: EPAR\u2014product information. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/zostavax. Accessed 14 Jan 2022."},{"key":"2305_CR46","unstructured":"European Medicines Agency. Zostavax summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/zostavax. Accessed 15 Nov 2021."},{"key":"2305_CR47","unstructured":"U.S. Food and Drug Administration. Shingrix prescribing information. https:\/\/www.fda.gov\/media\/108597\/download. Accessed 15 Nov 2021."},{"key":"2305_CR48","unstructured":"European Medicines Agency. EPAR\u2014Shingrix product information. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/shingrix. Accessed 14 Jan 2022."},{"key":"2305_CR49","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s12879-019-3719-7","volume":"19","author":"S Ohfuji","year":"2019","unstructured":"Ohfuji S, Ito K, Inoue M, Ishibashi M, Kumashiro H, Hirota Y, Kayano E, Ota N. Safety of live attenuated varicella-zoster vaccine in patients with underlying illnesses compared with healthy adults: a prospective cohort study. BMC Infect Dis. 2019;19:95.","journal-title":"BMC Infect Dis"},{"key":"2305_CR50","doi-asserted-by":"publisher","first-page":"3605","DOI":"10.1016\/j.vaccine.2019.04.046","volume":"37","author":"WS Choi","year":"2019","unstructured":"Choi WS, Choi JH, Jung DS, Choi HJ, Kim Y-S, Lee J, Jang H-C, Shin E-C, Park J-S, Kim H, Cheong HJ. Immunogenicity and safety of a new live attenuated herpes zoster vaccine (NBP608) compared to Zostavax\u00ae in healthy adults aged 50 years and older. Vaccine. 2019;37:3605\u201310.","journal-title":"Vaccine"},{"key":"2305_CR51","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1056\/NEJMoa051016","volume":"352","author":"MN Oxman","year":"2005","unstructured":"Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, Arbeit RD, Simberkoff MS, Gershon AA, Davis LE, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005;352:2271\u201384.","journal-title":"N Engl J Med"},{"key":"2305_CR52","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1093\/cid\/cir970","volume":"54","author":"KE Schmader","year":"2012","unstructured":"Schmader KE, Levin MJ, Gnann JW Jr, McNeil SA, Vesikari T, Betts RF, Keay S, Stek JE, Bundick ND, Su S-C, et al. Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50\u201359 years. Clin Infect Dis. 2012;54:922\u20138.","journal-title":"Clin Infect Dis"},{"key":"2305_CR53","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1001\/jama.2010.1983","volume":"305","author":"HF Tseng","year":"2011","unstructured":"Tseng HF, Smith N, Harpaz R, Bialek SR, Sy LS, Jacobsen SJ. Herpes zoster vaccine in older adults and the risk of subsequent herpes zoster disease. JAMA. 2011;305:160\u20136.","journal-title":"JAMA"},{"key":"2305_CR54","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1093\/aje\/kwx245","volume":"187","author":"R Baxter","year":"2018","unstructured":"Baxter R, Bartlett J, Fireman B, Marks M, Hansen J, Lewis E, Aukes L, Chen Y, Klein NP, Saddier P. Long-term effectiveness of the live zoster vaccine in preventing shingles: a cohort study. Am J Epidemiol. 2018;187:161\u20139.","journal-title":"Am J Epidemiol"},{"key":"2305_CR55","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001420","volume":"10","author":"SM Langan","year":"2013","unstructured":"Langan SM, Smeeth L, Margolis DJ, Thomas SL. Herpes zoster vaccine effectiveness against incident herpes zoster and post-herpetic neuralgia in an older US population: a cohort study. PLoS Med. 2013;10: e1001420.","journal-title":"PLoS Med"},{"key":"2305_CR56","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1016\/j.vaccine.2021.01.067","volume":"39","author":"J Lin","year":"2021","unstructured":"Lin J, Dobbins T, Wood JG, Bernardo C, Stocks NP, Liu B. Effectiveness of the live-attenuated herpes zoster vaccine 2 years after its introduction in Australia. Vaccine. 2021;39:1493\u20138.","journal-title":"Vaccine"},{"key":"2305_CR57","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","volume":"372","author":"H Lal","year":"2015","unstructured":"Lal H, Cunningham AL, Godeaux O, Chlibek R, Diez-Domingo J, Hwang SJ, Levin MJ, McElhaney JE, Poder A, Puig-Barbera J, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015;372:2087\u201396.","journal-title":"N Engl J Med"},{"key":"2305_CR58","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1056\/NEJMoa1603800","volume":"375","author":"AL Cunningham","year":"2016","unstructured":"Cunningham AL, Lal H, Kovac M, Chlibek R, Hwang SJ, Diez-Domingo J, Godeaux O, Levin MJ, McElhaney JE, Puig-Barbera J, et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N Engl J Med. 2016;375:1019\u201332.","journal-title":"N Engl J Med"},{"key":"2305_CR59","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1093\/cid\/ciab121","volume":"73","author":"Y Sun","year":"2021","unstructured":"Sun Y, Kim E, Kong CL, Arnold BF, Porco TC, Acharya NR. Effectiveness of the recombinant zoster vaccine in adults aged 50 and older in the United States: a claims-based cohort study. Clin Infect Dis. 2021;73:949\u201356.","journal-title":"Clin Infect Dis"},{"key":"2305_CR60","doi-asserted-by":"publisher","first-page":"3974","DOI":"10.1016\/j.vaccine.2021.05.056","volume":"39","author":"Y Sun","year":"2021","unstructured":"Sun Y, Jackson K, Dalmon CA, Shapiro BL, Nie S, Wong C, Arnold BF, Porco TC, Acharya NR. Effectiveness of the recombinant zoster vaccine among Kaiser Permanente Hawaii enrollees aged 50 and older: a retrospective cohort study. Vaccine. 2021;39:3974\u201382.","journal-title":"Vaccine"},{"key":"2305_CR61","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1093\/cid\/ciab125","volume":"73","author":"HS Izurieta","year":"2021","unstructured":"Izurieta HS, Wu X, Forshee R, Lu Y, Sung H-M, Agger PE, Chillarige Y, Link-Gelles R, Lufkin B, Wernecke M, et al. Recombinant zoster vaccine (Shingrix): real-world effectiveness in the first 2 years post-licensure. Clin Infect Dis. 2021;73:941\u20138.","journal-title":"Clin Infect Dis"},{"key":"2305_CR62","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2021.07.023","author":"N Khan","year":"2021","unstructured":"Khan N, Wang L, Trivedi C, Pernes T, Patel M, Xie D, Yang Y-X. Efficacy of recombinant zoster vaccine in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2021. https:\/\/doi.org\/10.1016\/j.cgh.2021.07.023.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2305_CR63","doi-asserted-by":"publisher","first-page":"4199","DOI":"10.1016\/j.vaccine.2021.05.043","volume":"39","author":"GS Kochhar","year":"2021","unstructured":"Kochhar GS, Desai A, Caldera Do F, El Hachem S, Aoun E, Sandhu D, Mohan BP, Dulai PS, Farraye FA. Effectiveness of recombinant zoster vaccine (RZV) in patients with inflammatory bowel disease. Vaccine. 2021;39:4199\u2013202.","journal-title":"Vaccine"},{"key":"2305_CR64","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvacx.2019.100007","volume":"1","author":"K Bollaerts","year":"2019","unstructured":"Bollaerts K, Alexandridou M, Verstraeten T. Risk factors for modified vaccine effectiveness of the live attenuated zoster vaccine among the elderly in England. Vaccine X. 2019;1:100007.","journal-title":"Vaccine X"},{"key":"2305_CR65","doi-asserted-by":"publisher","first-page":"2865","DOI":"10.1080\/21645515.2019.1627818","volume":"15","author":"L Oostvogels","year":"2019","unstructured":"Oostvogels L, Heineman TC, Johnson RW, Levin MJ, McElhaney JE, Van den Steen P, Zahaf T, Dagnew AF, Chlibek R, Diez-Domingo J, et al. Medical conditions at enrollment do not impact efficacy and safety of the adjuvanted recombinant zoster vaccine: a pooled post-hoc analysis of two parallel randomized trials. Hum Vaccin Immunother. 2019;15:2865\u201372.","journal-title":"Hum Vaccin Immunother"},{"key":"2305_CR66","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1080\/14760584.2018.1495565","volume":"17","author":"N Lecrenier","year":"2018","unstructured":"Lecrenier N, Beukelaers P, Colindres R, Curran D, De Kesel C, De Saegher JP, Didierlaurent AM, Ledent EY, Mols JF, Mrkvan T, et al. Development of adjuvanted recombinant zoster vaccine and its implications for shingles prevention. Expert Rev Vaccines. 2018;17:619\u201334.","journal-title":"Expert Rev Vaccines"},{"key":"2305_CR67","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1016\/j.vaccine.2020.12.076","volume":"39","author":"B Ackerson","year":"2021","unstructured":"Ackerson B, Qian L, Sy LS, Bruxvoort K, Wu J, Luo Y, Diaz-Decaro J, Talarico C, Tseng HF. Completion of the two-dose recombinant zoster vaccine series in adults 50 years and older. Vaccine. 2021;39:926\u201332.","journal-title":"Vaccine"},{"key":"2305_CR68","doi-asserted-by":"publisher","first-page":"A1807","DOI":"10.1016\/j.chest.2021.07.1634","volume":"160","author":"B Yawn","year":"2021","unstructured":"Yawn B, Merrill D, Martinez S, Williams D, Cotton J, Callen E, Loskutova N. Healthcare professionals\u2019 vaccine recommendations in people with COPD. Chest. 2021;160:A1807\u20138.","journal-title":"Chest"},{"key":"2305_CR69","doi-asserted-by":"publisher","first-page":"A1850","DOI":"10.1016\/j.chest.2021.07.1658","volume":"160","author":"B Yawn","year":"2021","unstructured":"Yawn B, Merrill D, Martinez S, Williams D, Cotton J, Callen E, Loskutova N. Comparative vaccine hesitancy in people with COPD. Chest. 2021;160:A1850\u20131.","journal-title":"Chest"},{"key":"2305_CR70","unstructured":"European Medicines Agency. Shingrix summary of product characteristics. https:\/\/www.ema.europa.eu\/documents\/product-information\/shingrix-epar-product-information_en.pdf. Accessed 15 Nov 2021."},{"key":"2305_CR71","doi-asserted-by":"publisher","first-page":"80","DOI":"10.15585\/mmwr.mm7103a2","volume":"71","author":"TC Anderson","year":"2022","unstructured":"Anderson TC, Masters NB, Guo A, Shepersky L, Leidner AJ, Lee GM, Kotton CN, Dooling KL. Use of recombinant zoster vaccine in immunocompromised adults aged \u2265 19 years: recommendations of the Advisory Committee on Immunization Practices\u2014United States, 2022. MMWR Morb Mortal Wkly Rep. 2022;71:80\u20134.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2305_CR72","doi-asserted-by":"publisher","first-page":"103","DOI":"10.15585\/mmwr.mm6703a5","volume":"67","author":"KL Dooling","year":"2018","unstructured":"Dooling KL, Guo A, Patel M, Lee GM, Moore K, Belongia EA, Harpaz R. Recommendations of the Advisory Committee on immunization practices for use of herpes zoster vaccines. MMWR Morb Mortal Wkly Rep. 2018;67:103\u20138.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2305_CR73","first-page":"313","volume":"34","author":"Robert Koch Institute","year":"2019","unstructured":"Robert Koch Institute. Recommendations from the standing committee on vaccination at the Robert Koch Institute. Epidemiologisches Bulletin. 2019;34:313\u201364.","journal-title":"Epidemiologisches Bulletin"},{"key":"2305_CR74","unstructured":"Ministero della Salut. Aggiornamento sulla vaccinazione contro herpes zoster [update on herpes zoster vaccination]. https:\/\/www.trovanorme.salute.gov.it\/norme\/renderNormsanPdf?anno=2021&codLeg=79080&parte=1%20&serie=null. Accessed 15 Nov 2021."},{"key":"2305_CR75","unstructured":"Federal Office of Public Health of the Swiss Confederation = Office f\u00e9d\u00e9ral de la sant\u00e9 publique OFSP. OFSP-Bulletin47\/2021 Magazine d\u2019information pour professionnels de la sant\u00e9 et pour les m\u00e9dias. https:\/\/www.bag.admin.ch\/dam\/bag\/fr\/dokumente\/cc\/Kampagnen\/Bulletin\/2021\/bu-47-21.pdf.download.pdf\/BU_47_21_FR.pdf. Accessed Dec 2021."},{"key":"2305_CR76","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1007\/s00103-019-02882-5","volume":"62","author":"A Siedler","year":"2019","unstructured":"Siedler A, Koch J, Garbe E, Hengel H, von Kries R, Ledig T, Mertens T, Zepp F, \u00dcberla K. Background paper to the decision to recommend the vaccination with the inactivated herpes zoster subunit vaccine. Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz. 2019;62:352\u201376.","journal-title":"Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz"},{"key":"2305_CR77","unstructured":"Committee on Immunization of Quebec (CIQ)\u2014National Institute of Public Health. Vaccination of immunosuppressed individuals aged 18 to 49 years and adults with chronic diseases: adjuvanted subunit vaccine against shingles (Zona-SU). https:\/\/www.inspq.qc.ca\/publications\/2705. Accessed 15 Nov 2021."}],"container-title":["Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-022-02305-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12931-022-02305-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-022-02305-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,29]],"date-time":"2023-01-29T18:06:30Z","timestamp":1675015590000},"score":1,"resource":{"primary":{"URL":"https:\/\/respiratory-research.biomedcentral.com\/articles\/10.1186\/s12931-022-02305-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,28]]},"references-count":77,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2305"],"URL":"https:\/\/doi.org\/10.1186\/s12931-022-02305-1","relation":{},"ISSN":["1465-993X"],"issn-type":[{"value":"1465-993X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,28]]},"assertion":[{"value":"9 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"ES and CW are employees of GSK; ES is a shareholder. BY reports grants and personal fees (for consultation and participation in advisory boards) from GSK, grants from BI, grants from AZ, andgrants from TEVA, grants from Pulmonx. Outside the work on this manuscript. TW has received fees from GSK for lectures and participation in advisory boards, but not for work on this manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"35"}}